Mallinckrodt (NYSE: MNK) announced today that the first clinical data on MNK-795 will be presented at PAINWeek 2013, to be held September 4-7 in Las Vegas. MNK-795 is an extended-release oral formulation of oxycodone and acetaminophen that has been studied in clinical trials for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate. On July 29, Mallinckrodt announced that the U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application for MNK-795 and granted priority review.
The data to be presented include results from a human abuse liability (HAL) study comparing certain abuse-related characteristics of intact and tampered-with MNK-795 with that of intact and tampered-with Percocet®1 (an immediate-release oxycodone/acetaminophen formulation); single- and multi-dose pharmacokinetic studies that characterize the drug release profile with immediate- and extended- release components over the 12-hour dosing interval; and a study of the compound’s efficacy and safety in an acute pain model.
“We are pleased to share the first results from our MNK-795 clinical development program which, if approved, could be a critical milestone for us as an independent specialty pharmaceuticals company,” said Mark Trudeau, President and Chief Executive Officer of Mallinckrodt. “Mallinckrodt’s investment in MNK-795 exemplifies our longstanding commitment to provide medications for the treatment of patients with acute pain.”
Currently, there are no extended-release oxycodone/acetaminophen combinations on the market for acute pain. In clinical trials, MNK-795 has been studied as two tablets dosed every 12 hours. The dosage form was designed using technology with both immediate- and extended-release components and potentially tamper-resistant properties.
In all, 15 abstracts for MNK-795 will be presented, including the following:
Human Abuse Liability/tamper resistance abstracts
Efficacy and safety abstracts
Mallinckrodt is a leading global specialty pharmaceuticals business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The Company’s Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide with direct sales in roughly 50 countries and distribution in approximately 40 countries. The Company’s 2012 revenue totaled $2.1 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Any statements contained in this communication that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future financial condition and operating results, economic, business, competitive and/or regulatory factors affecting our business. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or Company actions to differ materially from what is expressed or implied by these statements. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, our ability to receive procurement and production quotas granted by the U.S. Drug Enforcement Administration, our ability to obtain and/or timely transport molybdenum-99 to our technetium-99m generator production facilities, customer concentration, cost-containment efforts of customers, purchasing groups, third-party payors and governmental organizations, our ability to successfully develop or commercialize new products, our ability to protect intellectual property rights, competition, our ability to integrate acquisitions of technology, products and businesses, product liability losses and other litigation liability, the reimbursement practices of a small number of large public or private issuers, complex reporting and payment obligation under healthcare rebate programs, changes in laws and regulations, conducting business internationally, foreign exchange rates, material health, safety and environmental liabilities, litigation and violations and information technology infrastructure. These and other factors are identified and described in more detail in the “Risk Factors” section of the Form 10 Registration Statement, as amended. We disclaim any obligation to update these forward-looking statements other than as required by law.
1 Percocet is a registered trademark of Endo Pharmaceuticals Inc.
Lynn Phillips, 314-654-3263
Manager, Media Relations
Meredith Fischer, 314-654-6595
Senior Vice President, Communications
John Moten, 314-654-6650
Vice President, Investor Relations
|Mallinckrodt Pharmaceuticals Reports Human Abuse Liability (HAL) Data for MNK-795, an Extended-Release Oxycodone/Acetaminophen Combination (2013/9/4)|
|Mallinckrodt Pharmaceuticals Announces Positive Phase 3 Efficacy Results for MNK-795, an Extended-Release Oxycodone/Acetaminophen Combination (2013/9/5)|
|U.S. Food and Drug Administration (FDA) Extends Review of Mallinckrodt’s New Drug Application for XARTEMIS™ XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII) (2013/11/25)|
|Mallinckrodt Pharmaceuticals Presented 15 Posters on Investigational Drug at PAINWeek 2013 (2013/9/6)|
|/ CORRECTION - Threshold Pharmaceuticals Announces Early Clinical Data for Combining TH-302 With Antiangiogenic Agents in Advanced Solid Tumors (2013/10/21)|
|Mallinckrodt Pharmaceuticals Extends Patent Coverage for Octreoscan™ (Kit for the Preparation of Indium In-111 Pentetreotide) (2013/10/9)|
|Pfizer Inc. Continues Development Program for Remoxy® (oxycodone) Extended-Release Capsules CII (2013/10/22)|
|Threshold Pharmaceuticals Announces Early Clinical Data for Combining TH-302 With Antiangiogenic Agents in Advanced Solid Tumors (2013/10/21)|
|Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference (2013/9/9)|
|Catalyst Pharmaceutical Partners Announces Recommendation of Data Monitoring Committee to Continue Pivotal Phase lll Clinical Trial for Firdapse(TM) (2013/10/15)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.